Wedbush Reduces Earnings Estimates for Travere Therapeutics

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at Wedbush reduced their Q4 2025 EPS estimates for shares of Travere Therapeutics in a research report issued to clients and investors on Monday, February 24th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $0.12 for the quarter, down from their previous estimate of $0.15. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share. Wedbush also issued estimates for Travere Therapeutics' FY2026 earnings at $1.35 EPS, FY2027 earnings at $3.23 EPS and FY2028 earnings at $3.75 EPS.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The business had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million.

Several other brokerages have also recently weighed in on TVTX. Piper Sandler increased their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday, November 14th. HC Wainwright increased their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, January 15th. Citigroup increased their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Cantor Fitzgerald reissued an "overweight" rating on shares of Travere Therapeutics in a research report on Friday, February 21st. Finally, Barclays increased their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an "overweight" rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $30.62.

Remove Ads

Travere Therapeutics Trading Up 3.7 %

TVTX traded up $0.76 during trading on Wednesday, hitting $21.40. 2,003,508 shares of the stock traded hands, compared to its average volume of 1,656,869. The firm has a market capitalization of $1.90 billion, a P/E ratio of -5.22 and a beta of 0.72. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm has a 50-day moving average of $20.05 and a 200 day moving average of $17.00. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $25.29.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Rock Springs Capital Management LP lifted its position in Travere Therapeutics by 6.2% during the 4th quarter. Rock Springs Capital Management LP now owns 4,973,649 shares of the company's stock valued at $86,641,000 after acquiring an additional 289,173 shares during the period. Renaissance Technologies LLC increased its stake in Travere Therapeutics by 28.5% during the 4th quarter. Renaissance Technologies LLC now owns 2,409,514 shares of the company's stock valued at $41,974,000 after purchasing an additional 534,500 shares in the last quarter. Driehaus Capital Management LLC increased its stake in Travere Therapeutics by 608.1% during the 4th quarter. Driehaus Capital Management LLC now owns 2,217,975 shares of the company's stock valued at $38,637,000 after purchasing an additional 1,904,733 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Travere Therapeutics by 36.7% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 2,174,213 shares of the company's stock valued at $37,875,000 after purchasing an additional 583,836 shares in the last quarter. Finally, Emerald Advisers LLC increased its stake in Travere Therapeutics by 8.4% during the 4th quarter. Emerald Advisers LLC now owns 2,125,744 shares of the company's stock valued at $37,030,000 after purchasing an additional 165,085 shares in the last quarter.

Insider Activity at Travere Therapeutics

In related news, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,927 shares of the company's stock, valued at $945,842.94. This trade represents a 21.45 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP William E. Rote sold 5,200 shares of Travere Therapeutics stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total transaction of $122,356.00. Following the transaction, the senior vice president now directly owns 98,519 shares of the company's stock, valued at approximately $2,318,152.07. This trade represents a 5.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 206,335 shares of company stock valued at $4,453,012 in the last three months. Company insiders own 3.75% of the company's stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.